Author's posts
Pharma CEOs survive Senate grilling with few concessions
Pharmaceutical executives took a verbal beating, but didn’t concede much in a high-profile testimony before the Senate Finance Committee.
Louisiana looking for new Medicaid managed-care companies
The Lousiana Department of Health issued a request for proposals on Monday for managed-care companies hoping to serve the state’s more than 1.5 million Medicaid members starting in 2020.
Interior design is having its moment in healthcare
A pair of crystal chandeliers illuminate the open bar stocked with infused waters and teas rich in antioxidants. Air-purifying fiddle-leaf fig plants draw your eye up to the recessed gold ceiling. Swedish Covenant Health has opened up an…
Anthem/Cigna damages trial reveals infighting
Anthem officials told a judge on Monday that their counterparts at Cigna sabotaged the $48.9 billion merger deal, even refusing to divest business lines that would have won them approval by regulators.
DOJ asks judge to approve CVS/Aetna deal
The U.S. Justice Department asked a judge on Monday to formally approve the merger between CVS Health and insurer Aetna.
5 things to watch in the Senate’s major drug price hearing
Here are five issues to watch out for during Tuesday’s blockbuster drug prices hearing.
New GOP healthcare bill targets costs, hospital consolidation
Ambitious new bill from GOP Rep. Bruce Westerman aims to tackle costs along with an Obamacare market overhaul.
Tenet in exclusive talks over potential Conifer deal
Tenet Healthcare Corp. has entered into exclusive talks over a potential deal for Conifer Health Solutions, and has set a goal of cutting another $200 million in costs by the end of 2019.
Grassley revives probe of tax-exempt hospitals
Sen. Chuck Grassley (R-Iowa) signals he will leverage his powerful Senate Finance Committee chairmanship to make sure not-for-profit hospitals are doling out enough charity care.
Generic-drug approval growth doesn’t spark competition
The first three generics introduced make the biggest dent on prices. But the vast majority of generic-drug approvals from 2012 to 2017 were for the fourth, fifth, sixth or even later versions that minimally impact prices, according to a new report.
